We could, then, base our tumor selection for sensitivity on the balance between p-AKT, p-ERK, MYC or mTor, which concomitantly or independently are modulating the sensitivity to rapamycin and irinotecan, and in the absence of an isolated HIF-2α over-expression. The gene discussed is MTOR; the disease is neoplasm.